J. McHutchison

LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY

Stefan Zeuzem, Sulkowski, Fabien Zoulim et al. · 2010 · 53 citations

Interim Analysis, Hepatology, Hepatitis C +9

991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

Mark Sulkowski, E. Läwitz, M. Shiffman et al. · Journal of Hepatology · 2008 · 47 citations

Clinical Trials, Therapeutic Efficacy, The Ideal +8

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

M.P. Manns, Andrew J. Muir, Nathalie Adda et al. · Journal of Hepatology · 2009 · 34 citations

Hepatology, Hepatitis C, Viral Hepatitis +10

Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study

Edward Gane, M.L. Shiffman, K. Peter Etzkorn et al. · Journal of Hepatology · 2016 · 32 citations

Effective Retreatment, Gs-us-342-1553 Study, Pharmacology +6

92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

E. Läwitz, Curtis Cooper, M. Rodríguez‐Torres et al. · Journal of Hepatology · 2009 · 26 citations

Viral Hepatitis, Antiviral Drug Development, Antiviral Therapy +5